FDA “Unmet Medical Need” Definition Can Be Moving Target – ImClone CEO
Executive Summary
Biotech product development would be helped by more flexibility from FDA in applying the standard of an "unmet medical need," ImClone CEO Harlan Waksal suggested during a June 3 Manhattan Institute Capitol Hill briefing on the future of medical progress
You may also be interested in...
Big Pharma Likes Big Trials, Biotech CEO Says; Tufts Defends R&D Estimate
Large pharmaceutical companies are comfortable with high R&D costs because they create a barrier to entry in the industry, Cancer Therapeutics, Inc. CEO Robert Oldham, MD, maintained during a Capitol Hill briefing sponsored by the Manhattan Institute June 3
ImClone Erbitux Hearing Will Include Five FDAers Under Subpoena
The House Energy & Commerce/Oversight Subcommittee has subpoenaed five FDA witnesses to appear at a June 13 hearing on issues surrounding the refuse-to-file letter for ImClone's Erbitux
Big Pharma Likes Big Trials, Biotech CEO Says; Tufts Defends R&D Estimate
Large pharmaceutical companies are comfortable with high R&D costs because they create a barrier to entry in the industry, Cancer Therapeutics, Inc. CEO Robert Oldham, MD, maintained during a Capitol Hill briefing sponsored by the Manhattan Institute June 3